Ophthalmology

The worldwide burden of vision loss continues to climb, but there may be solutions with regards to better access to care and improved screening.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.

The NDA was granted Priority Review designation with a PDUFA target action date of November 26, 2022.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.

Nonmetropolitan counties have a lower density of ophthalmologists compared to metropolitan counties.

A faster rate and central location of GCC thinning was associated with lower vision-related quality of life.

An analysis from Duke University School of Medicine suggests few PCPs were performing fundoscopy to identify diabetic retinopathy in patients with type 2 diabetes and even those who did were often accurate just 63% of the time.

Dr. Rocha discusses treatment options, overall safety, and patient populations undergoing surgery.

Usage of subtenon and regional anesthesia decreased, while general and combined topical and intracameral anesthesia was stable.

However, vision is no longer significantly improved after 4 years of using anti-VEGF therapies.

After implantation, investigators observed very good distance, intermediate and near functional visual outcomes and a high percentage of subjects without visual disturbances.

The investigators labeled pre-existing glaucoma, high preoperative intraocular pressure, and combined keratoplasty with removal or exchange of an intraocular lens were definitely associated with an increased risk.

Investigators presented the study at the Netherlands Ophthalmological Society Annual Congress, noting a potential cause for this trend could be the heightened cautiousness of surgical teams following the 2 month intermission due to the COVID-19 pandemic.

At 12 months, the mean VA change from baseline was 17.6 for BRVO patients and 18.6 for CRVO patients in the Netherlands.

The eyelid maneuvers increased intraocular pressure by ≥40mm Hg in patients with primary open-angle glaucoma.

Patients with RVO in a nationwide cohort in Denmark had an increased risk to develop overall, ischemic and non-ischemic CVD compared to non-RVO control patients.

A deep learning system provided accurate predictions of occurrence and severity of ROP ≤45 weeks’ PMA based on retinal photographs at first screening.

Combination treatment was equal to anti-VEGF monotherapy in functional and structural outcomes in the treatment of macular edema due to BRVO.